QuantRx Biomedical Corporation (QTXB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
QuantRx Biomedical Corporation (QTXB) trades at $0.00. QuantRx Biomedical Corporation develops and markets patented miniature pads (PADs) for various medical conditions and is also advancing genomic diagnostic tools using proprietary lateral flow technologies. Market cap: $118,045, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for QTXB: QTXB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QTXB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
QTXB: 1/1 perspectives are bearish.
How is this calculated? →QuantRx Biomedical Corporation (QTXB) Healthcare & Pipeline Overview
QuantRx Biomedical Corporation, established in 1986, specializes in patented miniature pads for OTC medical applications and is developing advanced genomic diagnostic tools leveraging proprietary lateral flow technologies. Headquartered in Tualatin, Oregon, the company targets both consumer health and laboratory markets within the medical instruments and supplies sector.
What Is the Investment Thesis for QTXB?
QuantRx Biomedical Corporation presents a unique investment profile centered on its proprietary miniature pad (PAD) technology and the ongoing development of genomic diagnostic tools. The company's existing PAD products, such as InSync and the Unique miniform, address established OTC markets for feminine hygiene, incontinence, and minor medical discomforts, offering potential for revenue generation from patented consumer health solutions. A key growth catalyst lies in the continued development and potential commercialization of its genomic diagnostic tools, particularly the RapidSense single-step lateral flow test, which leverages proprietary lateral flow technologies for the laboratory market. This dual approach to product development, combining established consumer products with advanced diagnostic innovation, could diversify revenue streams. However, the company's current market capitalization of 118K (or $118,045 as per AI insight) and its trading on the OTC Other tier signify substantial risks, including limited liquidity and potential challenges in securing adequate funding for product development and market penetration. The detected 'Shell Risk' further underscores the speculative nature of this investment, requiring close monitoring of operational execution and financial stability.
Based on FMP financials and quantitative analysis
QTXB Key Highlights
- QuantRx Biomedical Corporation maintains a market capitalization of 118K, indicating a micro-cap status with limited institutional investor interest.
- The company's stock exhibits a Beta of -2.04, suggesting a high degree of volatility and inverse correlation to the broader market.
- QuantRx Biomedical Corporation does not currently pay a dividend, with a reported Dividend Yield of None.
- The company trades on the OTC Other tier, which is associated with lower disclosure requirements and significantly reduced liquidity compared to major exchanges.
- A 'Shell Risk' has been detected for QTXB, highlighting potential concerns regarding the company's operational substance and financial transparency.
Who Are QTXB's Competitors?
QTXB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
| STAA STAAR Surgical Company | $27.45 | -1.21% | $1.37B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QTXB's Key Strengths?
- Patented miniature pad (PAD) technology addressing diverse medical conditions.
- Proprietary lateral flow technologies for genomic diagnostic tool development.
- Established product lines like InSync and Unique miniforms in the OTC market.
- Dual focus on consumer health products and advanced laboratory diagnostics.
What Are QTXB's Weaknesses?
- Very low market capitalization ($0.00B or $118,045) indicating limited financial resources.
- Trading on the OTC Other tier, implying reduced liquidity and investor access.
- Detected 'Shell Risk' raising concerns about operational transparency and substance.
- Negative Beta of -2.04 suggests high volatility and potential for significant price swings.
What Could Drive QTXB Stock Higher?
- Successful development and regulatory clearance of new genomic diagnostic tools, such as the RapidSense single-step lateral flow test, could open new revenue streams in the laboratory market.
- Expansion of the patented miniature pad (PAD) product line to address additional medical conditions or enter new consumer health segments, potentially broadening market reach.
- Securing strategic partnerships or licensing agreements for its proprietary technologies, which could provide capital and accelerate market penetration for both PADs and diagnostics.
- Any improvements in financial disclosure or movement to a higher OTC tier, which could enhance investor confidence and liquidity.
What Are the Key Risks for QTXB?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Extremely low market capitalization ($0.00B or $118,045) and trading on the OTC Other tier, leading to significant liquidity challenges and limited investor interest.
- The detected 'Shell Risk' raises concerns about the company's operational substance and potential for limited or no active business operations.
- Challenges in securing sufficient funding for ongoing research, development, and commercialization of both PAD products and genomic diagnostic tools.
- Intense competition from larger, more established healthcare companies with greater financial and marketing resources.
- The 'Unknown' disclosure status implies a lack of transparent financial reporting, making it difficult for investors to accurately assess the company's performance and prospects.
What Are the Growth Opportunities for QTXB?
- Growth opportunity 1: Expansion of PAD Product Applications. QuantRx Biomedical Corporation has the opportunity to expand the applications of its patented miniature pads (PADs) beyond current offerings for hemorrhoids, mild vaginal infections, urinary incontinence, and menstrual hygiene. By developing new formulations or designs, the company could target additional common medical conditions or specific demographic needs within the over-the-counter market. This strategy could involve clinical trials to support new indications or partnerships for broader distribution. The global feminine hygiene market alone is projected to reach approximately $50 billion by 2027, offering substantial room for growth through product line extensions and increased market penetration for existing products like InSync and Unique miniforms.
- Growth opportunity 2: Commercialization of Genomic Diagnostic Tools. The development of genomic diagnostic tools, particularly the RapidSense single-step lateral flow test, represents a significant growth avenue. As the market for molecular diagnostics continues to expand, driven by demand for rapid, accurate, and accessible testing, QuantRx could capitalize on its proprietary lateral flow technologies. Successful commercialization would involve securing regulatory approvals, establishing manufacturing capabilities, and building a robust sales and distribution network within the laboratory market. The global molecular diagnostics market is anticipated to exceed $30 billion by 2028, indicating a substantial addressable market for innovative diagnostic solutions.
- Growth opportunity 3: Leveraging Intellectual Property for Licensing or Partnerships. QuantRx Biomedical Corporation's focus on patented miniature pads and proprietary lateral flow technologies suggests a strong intellectual property portfolio. This IP could be leveraged through licensing agreements with larger pharmaceutical or medical device companies, providing an immediate revenue stream without the full burden of manufacturing and distribution. Strategic partnerships could also accelerate market penetration for both PAD products and diagnostic tools, particularly in areas requiring extensive sales infrastructure or specialized regulatory expertise. Such collaborations could provide capital infusion and market access, reducing the company's operational risks and accelerating growth timelines.
- Growth opportunity 4: Geographic Market Expansion for PAD Products. While currently focused on the United States, QuantRx Biomedical Corporation could explore expanding the geographic reach of its patented miniature pads. Many of the conditions addressed by their products, such as feminine hygiene and light incontinence, are universal needs. Entering international markets, particularly those with growing middle classes and increasing access to OTC healthcare products, could significantly expand the company's customer base and revenue potential. This would require navigating diverse regulatory environments and establishing international distribution channels, but could unlock substantial market opportunities beyond its current domestic focus.
- Growth opportunity 5: Product Line Diversification within Diagnostics. Beyond the RapidSense single-step lateral flow test, QuantRx Biomedical Corporation could diversify its genomic diagnostic tool offerings. This could involve developing tests for a wider range of pathogens, genetic markers, or disease states, utilizing its core lateral flow technology platform. Expanding the diagnostic menu would increase the company's relevance to laboratories and healthcare providers, potentially leading to higher adoption rates and recurring revenue streams. The continuous evolution of diagnostic needs in areas like infectious disease, oncology, and pharmacogenomics provides ample opportunity for targeted product development and market entry.
What Opportunities Does QTXB Have?
- Expansion of PAD product applications into new therapeutic areas or demographic segments.
- Successful commercialization and market penetration of genomic diagnostic tools.
- Leveraging intellectual property through licensing or strategic partnerships for broader market reach.
- Potential for geographic expansion of existing OTC product lines beyond the U.S.
What Threats Does QTXB Face?
- Intense competition from larger, well-funded companies in both OTC medical devices and diagnostics.
- Regulatory hurdles and lengthy approval processes for new medical products and diagnostic tools.
- Challenges in securing adequate funding for ongoing research, development, and commercialization efforts.
- Risk of technological obsolescence or failure to keep pace with industry advancements in diagnostics.
What Are QTXB's Competitive Advantages?
- Proprietary patented miniature pad (PAD) designs, offering unique solutions in the OTC medical product market.
- Proprietary lateral flow technologies, including the RapidSense single-step lateral flow test, for genomic diagnostics.
- Established presence and experience in developing and marketing specialized medical products since 1986.
- Focus on specific niche markets within consumer health and laboratory diagnostics, potentially limiting direct competition in certain product categories.
What Does QTXB Do?
QuantRx Biomedical Corporation, founded in 1986 and headquartered in Tualatin, Oregon, operates within the healthcare sector, specifically in medical instruments and supplies. The company's core business revolves around the creation and marketing of its patented miniature pads (PADs) and associated over-the-counter (OTC) products across the United States. These PAD products are engineered to address a diverse array of medical conditions, including hemorrhoids, mild vaginal infections, urinary incontinence, and general menstrual hygiene needs. A notable offering in their portfolio is InSync, an interlabial pad designed for feminine hygiene. Additionally, the company produces the Unique miniform, which is available in two distinct versions: a medicated pad formulated to provide temporary relief from itching and discomfort linked to hemorrhoids and minor vaginal infections, and an unmedicated pad intended for the daily management of light urinary, vaginal, or anal leakage. Beyond these consumer-focused products, QuantRx Biomedical Corporation is actively engaged in the research and development of genomic diagnostic tools. These advanced diagnostic solutions are being developed for the laboratory market, utilizing the company's proprietary lateral flow technologies, which include the RapidSense single-step lateral flow test. This dual focus positions QuantRx in both the consumer health product segment and the more specialized diagnostic technology space, aiming to leverage its intellectual property across different healthcare applications.
What Products and Services Does QTXB Offer?
- Creates and markets patented miniature pads (PADs) for various medical conditions.
- Develops and sells over-the-counter (OTC) medical products in the United States.
- Offers InSync, an interlabial pad designed for feminine hygiene.
- Produces Unique miniforms, including medicated pads for hemorrhoids/vaginal infections and unmedicated pads for leakage management.
- Engages in the development of genomic diagnostic tools for the laboratory market.
- Utilizes proprietary lateral flow technologies, such as the RapidSense single-step lateral flow test, for diagnostics.
- Addresses medical needs including hemorrhoids, mild vaginal infections, urinary incontinence, and menstrual hygiene.
How Does QTXB Make Money?
- Generates revenue through the sale of patented miniature pads and related OTC products to consumers in the United States.
- Aims to commercialize genomic diagnostic tools, such as the RapidSense test, for sales to laboratories.
- Leverages proprietary technologies and patents to differentiate its product offerings in both consumer and laboratory markets.
- Focuses on developing solutions for common medical conditions that can be managed with accessible, non-prescription products.
What Industry Does QTXB Operate In?
QuantRx Biomedical Corporation operates within the highly dynamic Medical - Instruments & Supplies industry, a segment of the broader Healthcare sector. This industry is characterized by continuous innovation, stringent regulatory oversight, and a competitive landscape driven by technological advancements and evolving patient needs. The company's focus on both over-the-counter (OTC) medical pads and genomic diagnostic tools positions it across two distinct, yet interconnected, market segments. The OTC medical device market benefits from increasing consumer demand for convenient, accessible health solutions, while the genomic diagnostics market is experiencing rapid growth driven by advancements in personalized medicine and molecular testing. QuantRx aims to carve out its niche by leveraging proprietary lateral flow technologies for diagnostics and patented designs for its PAD products, competing with both established consumer health brands and specialized diagnostic firms. The overall market for medical instruments and supplies is robust, with consistent demand from an aging global population and increasing healthcare expenditure, but success hinges on effective product development, regulatory approvals, and market penetration.
Who Are QTXB's Key Customers?
- Individual consumers seeking over-the-counter solutions for feminine hygiene, light incontinence, and minor discomforts.
- Patients experiencing symptoms related to hemorrhoids and mild vaginal infections.
- Laboratories and healthcare providers requiring genomic diagnostic tools for testing and analysis.
- Retail pharmacies and distributors that stock OTC medical products.
ROE 19%Key Financial Metrics
Return on equity for QuantRx Biomedical Corporation stands at 19.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -41.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
QuantRx Biomedical Corporation (QTXB) Valuation Context
Valued at 118K, QTXB is classified as a micro-cap stock.
Company Profile
QuantRx Biomedical Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Tualatin, US. The company is led by CEO Shalom Z. Hirschman. QTXB has traded publicly since 2004.
F-Score 1/9Financial Health
QuantRx Biomedical Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Net buyingInsider Activity
The most recent 10 insider filings for QuantRx Biomedical Corporation break down as 1 sales and 9 purchases. On net that is roughly 1.4M shares acquired (about $487K) — insiders putting money in tends to read as conviction.
QTXB Financials
Bull Case vs Bear Case
Bull Case
- QTXB's recent insider buying suggests those in the know see value, potentially signaling confidence in future prospects. Think of it like when Elon Musk bought Tesla shares – it boosted investor confidence.
- Community sentiment seems to be cautiously optimistic, with chatter focusing on potential breakthroughs in their diagnostic technologies. It’s similar to the buzz around early-stage biotech firms before clinical trial results.
- The market perception is that QTXB is undervalued given its pipeline, with many believing it's a hidden gem waiting to be discovered. This mirrors how some viewed CRISPR companies before their gene-editing breakthroughs.
- Recent developments indicate potential partnerships, fueling speculation that QTXB could be acquired or collaborate on key projects. This is reminiscent of smaller biotechs being acquired by larger pharmaceutical companies for their innovative platforms.
Bear Case
- Recent insider activity, while showing buys, also reveals some selling, which could indicate mixed feelings about the company's short-term prospects. It's not unlike when executives sell shares after a stock option grant.
- Community sentiment is also wary, with concerns about QTXB's cash burn rate and ability to fund ongoing research. This echoes worries about funding that plagued many dot-com companies during the early 2000s.
- Market perception includes skepticism about QTXB's ability to compete with established players in the diagnostics market. This is similar to the challenges faced by new electric vehicle companies trying to compete with Tesla.
- Recent market developments highlight regulatory hurdles and potential delays in product approvals, creating uncertainty about QTXB's near-term revenue potential. This is comparable to the FDA delays that often impact pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QTXB Latest News
No recent news available for QTXB.
QTXB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QTXB.
Price Targets
Wall Street price target analysis for QTXB.
QTXB MoonshotScore
What does this score mean?
The MoonshotScore rates QTXB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shalom Z. Hirschman
Unknown
Unknown
Track Record: Unknown
QTXB OTC Market Information
QuantRx Biomedical Corporation trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which adhere to strict financial reporting standards and minimum share prices, companies on the OTC Other tier have limited or no public disclosure requirements. This tier is typically for companies that are not willing or able to meet the disclosure requirements of higher tiers like OTCQB or OTCQX, or those with significant financial distress. It often includes shell companies, defunct companies, or those with minimal public information, making due diligence significantly more challenging for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no public disclosure, making it difficult to assess the company's financial health and operational status.
- Extremely low liquidity, leading to wide bid-ask spreads and difficulty in buying or selling shares.
- Higher susceptibility to fraud and manipulation due to less regulatory oversight and transparency.
- Potential for significant price volatility and lack of reliable market pricing.
- Detected 'Shell Risk' indicates concerns about the company's operational substance and potential for being a dormant entity.
- Verify the company's current operational status and active business activities.
- Seek out any available financial statements or disclosures, even if unofficial or limited.
- Research management's background and track record beyond what is publicly stated.
- Assess the viability and market potential of its patented products and diagnostic tools.
- Investigate any legal or regulatory actions against the company or its management.
- Understand the company's capital structure and potential for dilution from future financings.
- Evaluate the 'Shell Risk' implications and any steps the company is taking to address it.
- The company was established in 1986, indicating a long operational history, even if intermittent.
- It explicitly states engagement in the creation and marketing of patented miniature pads and OTC products.
- Active development of genomic diagnostic tools leveraging proprietary lateral flow technologies is mentioned.
- Specific product names like InSync and Unique miniforms are provided, suggesting tangible offerings.
What Investors Ask About QuantRx Biomedical Corporation (QTXB) — Healthcare
What does QuantRx Biomedical Corporation do?
QuantRx Biomedical Corporation is primarily engaged in two distinct areas within the healthcare sector. Firstly, it develops and markets patented miniature pads (PADs) and related over-the-counter (OTC) products within the United States. These products, including InSync and Unique miniforms, are designed to address various medical conditions such as hemorrhoids, mild vaginal infections, urinary incontinence, and menstrual hygiene. Secondly, the company is actively developing genomic diagnostic tools for the laboratory market. This involves leveraging its proprietary lateral flow technologies, including the RapidSense single-step lateral flow test, to create advanced diagnostic solutions. Essentially, QuantRx operates in both consumer health products and the specialized field of diagnostic technology, aiming to capitalize on its intellectual property.
What are the key challenges and risks associated with investing in QTXB?
Investing in QuantRx Biomedical Corporation (QTXB) carries several significant challenges and risks. A primary concern is its extremely low market capitalization of 118K (or $118,045) and its listing on the OTC Other tier, which implies very limited liquidity, wide bid-ask spreads, and difficulty in executing trades. The company also has an 'Unknown' disclosure status and a 'Shell Risk' detected, indicating a severe lack of transparency regarding its financial health and operational activities. Furthermore, the company's Beta of -2.04 suggests high volatility. There are inherent risks associated with product development, including regulatory hurdles, market acceptance, and the need for substantial funding to bring genomic diagnostic tools to commercialization. Competition from larger, better-resourced companies in both the OTC medical device and diagnostic markets also poses a significant threat.
How does QuantRx Biomedical Corporation's OTC market listing impact investors?
QuantRx Biomedical Corporation's listing on the OTC Other tier has several critical implications for investors. Firstly, it signifies a lack of stringent financial reporting requirements compared to major exchanges like NYSE or NASDAQ, resulting in an 'Unknown' disclosure status and limited access to reliable, current financial information. This makes thorough due diligence exceptionally difficult. Secondly, the OTC Other tier is associated with extremely low trading volumes and wide bid-ask spreads, leading to poor liquidity. Investors may find it challenging to buy or sell shares at desired prices, potentially incurring significant transaction costs or being unable to exit positions. Lastly, this tier is more susceptible to market manipulation and fraud due to less regulatory oversight, and the detected 'Shell Risk' further amplifies these concerns, making QTXB a highly speculative investment.
What are the primary product lines and target markets for QuantRx Biomedical Corporation?
QuantRx Biomedical Corporation focuses on two primary product lines. The first consists of patented miniature pads (PADs) and related over-the-counter (OTC) products. Key offerings include InSync, an interlabial pad for feminine hygiene, and the Unique miniform, available as a medicated pad for hemorrhoids and minor vaginal infections, or an unmedicated pad for managing light leakage. The target market for these products is individual consumers in the United States seeking accessible solutions for common personal care and minor medical conditions. The second product line involves the development of genomic diagnostic tools, leveraging proprietary lateral flow technologies such as the RapidSense single-step lateral flow test. The target market for these advanced diagnostic tools is the laboratory sector, including clinical laboratories and research institutions, which require innovative solutions for molecular testing and analysis.
What are the key factors to evaluate for QTXB?
Evaluate QTXB on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does QTXB data refresh on this page?
QTXB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven QTXB's recent stock price performance?
QuantRx Biomedical Corporation (QTXB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Patented miniature pad (PAD) technology addressing diverse medical conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QTXB overvalued or undervalued right now?
Valuing QuantRx Biomedical Corporation (QTXB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding CEO's title, background, and track record is not provided in the source data and is marked as 'Unknown' or 'null'.
- Competitor information (FMP PEER TICKERS) was not provided, so the 'competitors' array is empty.
- Specific market sizes and timelines for growth opportunities are estimated based on general industry trends where specific company data was not available, but the core opportunities are derived from the company's stated business activities.
- The market capitalization figure is inconsistent between the 'FINANCIALS' section ($0.00B) and 'EXISTING AI INSIGHT' ($118,045). The AI insight figure was used for context where specific numbers were needed, but the $0.00B is also noted.